MELISSA BADOWSKI, PHARMD, MPH, BCPS, AAHIVP

Gender-affirming hormone therapy (GAHT) therapy consists of administration of exogenous hormones and suppression of endogenous hormone production, with the goal of obtaining characteristics more congruent with an individual’s gender identity. Here is a review of these therapies and consideration for PrEP and the risks associated with HIV in this diverse population.

Unique considerations are called for when caring for intravenous drug users with newly diagnosed HIV/HCV coinfections.